U.S. markets open in 6 minutes
  • S&P Futures

    3,744.75
    +54.50 (+1.48%)
     
  • Dow Futures

    29,889.00
    +351.00 (+1.19%)
     
  • Nasdaq Futures

    11,501.00
    +215.25 (+1.91%)
     
  • Russell 2000 Futures

    1,744.10
    +29.20 (+1.70%)
     
  • Crude Oil

    85.55
    +1.92 (+2.30%)
     
  • Gold

    1,721.30
    +19.30 (+1.13%)
     
  • Silver

    21.07
    +0.48 (+2.34%)
     
  • EUR/USD

    0.9918
    +0.0091 (+0.92%)
     
  • 10-Yr Bond

    3.5910
    -0.0600 (-1.64%)
     
  • Vix

    29.18
    -2.44 (-7.72%)
     
  • GBP/USD

    1.1355
    +0.0035 (+0.31%)
     
  • USD/JPY

    144.7450
    +0.1250 (+0.09%)
     
  • BTC-USD

    20,011.06
    +702.85 (+3.64%)
     
  • CMC Crypto 200

    454.82
    +19.47 (+4.47%)
     
  • FTSE 100

    7,049.23
    +140.47 (+2.03%)
     
  • Nikkei 225

    26,992.21
    +776.42 (+2.96%)
     

Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned

·2 min read
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned

A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple.